Tyra Biosciences Inc
TYRAHealthcare|Biotechnology|USA
$32.75
-0.26 (-0.79%)
Tangible Book
$6.52
Earnings Power
$6.02
Upcoming Data Readouts (6)
Sep 2026
Est. completion
P1Locally Advanced Cholangiocarcinoma
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752n=40
Nov 2026
Est. completion
P1P2Locally Advanced Urothelial Carcinoma
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552n=310
Jan 2028
Est. completion
P1Metastatic Hepatocellular Carcinoma
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753n=100
Feb 2028
Est. completion
P2Low-grade NMIBC
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677n=90
Jan 2030
Est. completion
Oct 2030
Est. completion
P2Low Grade Upper Tract Urothelial Carcinoma
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947n=230
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
May 2025
P1
A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
NCT06006702